Skip to main content
2025 AAP National Conference and Exhibition Main banner
 
Session Icons
Closed Captioning
Closed Captioning
Livestream
Livestream
Presentado en Espanol
Presentado en Espanol
Sold Out Ticketed Session
Sold Out Ticketed Session
Special Event
Special Event
Ticketed Session
Ticketed Session
Traduccion Espanol
Traduccion Espanol
Poster Icons
Oral Presentation
Oral Presentation
Poster Presentation
Poster Presentation

Original Research

Program: Section on Integrative Medicine

O2104: Preliminary Findings on High-Dose Vitamin D Supplementation and Insulin Resistance in Adolescents with Obesity: Randomized Controlled Trial

Saturday, September 27, 2025
8:45 AM - 8:55 AM MDT
Location: Colorado Convention Center, Meeting Room 203
Oral Presentation
Background:

Background: Vitamin D (VD) levels tend to fall into deficient ranges in individuals with obesity, primarily due to sequestration by adipose tissue. Emerging evidence suggests an association between VD deficiency and various mechanisms involved in the development of insulin resistance.

Objective: To evaluate the effect of 4000 IU versus 1000 IU of cholecalciferol on HOMA-IR levels and body adiposity in adolescents with obesity.

Methods:

Methods: This randomized controlled trial (ClinicalTrials.gov ID: NCT06847373) included adolescents with obesity who were followed for six months. Participants were randomized to receive either 4000 IU/day or 1000 IU/day of cholecalciferol. Blood samples were collected at baseline and at six months to assess 25-hydroxyvitamin D, insulin, and glucose levels. Anthropometric measurements were also obtained. Statistical analyses compared changes in HOMA-IR, body fat percentage, and 25-hydroxyvitamin D levels within and between groups using paired and unpaired Student’s t-tests, respectively, following logarithmic data transformation.

Results: Preliminary

Results: A total of 20 participants met the eligibility criteria. Baseline characteristics were similar between groups, and all had VD levels < 30 ng/mL. After six months, the 4000 IU group showed a trend toward reductions in body fat and HOMA-IR, with 80% achieving VD levels >30 ng/mL. In contrast, the 1000 IU group experienced an increase in body fat (36.7% vs. 37.9%, p=0.004), and only 10% reached VD levels >30 ng/mL. When comparing changes between groups, the 4000 IU group demonstrated a significantly greater increase in 25-hydroxyvitamin D levels (23.5 ng/mL vs. 4.2 ng/mL, p< 0.001), a trend toward reduced body fat percentage (-0.09% vs. 1.24%, p=0.07), and lower HOMA-IR values (-0.09 vs. 0.75, p=0.25) compared to the 1000 IU group. No significant difference was observed in BMI Z-score (-0.03 vs. -0.00, p=0.37).

Conclusion:

Conclusion: In adolescents with obesity, supplementation with 4000 IU/day of cholecalciferol showed a trend toward improved insulin resistance and body fat reduction compared to 1000 IU/day after six months.